Label Error Delays Debut

Despite the promise of Genentech’s genetically engineered version of human growth hormone, the company learned the hard way last week that a good product doesn’t ensure smooth market entry.

Genentech expected to begin shipping the drug Protropin as early as last Friday, but the FDA discovered at the last minute that Genentech had printed incorrect information on the product’s label. Delivery will be delayed while Genentech reprints thousands of labels. Company spokesman say the FDA’s request is not unusual and that shipments will begin this week. It called the setback insignificant, but at least one potential customer didn’t see it that way.

“We went all the way to the hospital to get it,” says Megan McDermott, whose son Kevin needs the drug. “And when we got there they said there was some red tape and they don’t know whether it will be ready in days or in weeks. We were very disappointed. It was a bad day.”